Andrew Evens
0000-0002-6900-1824
Rutgers Cancer Institute of New Jersey
171 papers found
Refreshing results…
The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma associated with the use of biologic and other investigational agents: the importance of long-term post-marketing safety surveillance.
Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs.
Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports
Post-Transplantation Lymphoproliferative Disorders: Diagnosis, Prognosis, and Current Approaches to Therapy
Burkitt Lymphoma and Leukemia
Improving outcomes in PTLD.
Mitochondrial-mediated apoptosis in lymphoma cells by the diterpenoid lactone Andrographolide, the active component of Andrographis paniculata
Rituximab‐induced late onset neutropenia in newly‐diagnosed B‐cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism
Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options.
Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications
Reply to D. Dierickx et al
Motexafin Gadolinium Enhances p53-Mdm2 Interactions, Reducing p53 and Downstream Targets in Lymphoma Cell Lines
Hypoxia-Inducible Factor-1 α Expression Predicts Superior Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP
Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern Era
Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib Is Longer Compared with Other Histologic Subtypes
Primary cutaneous and systemic anaplastic large cell lymphoma
Curing Hodgkin's lymphoma: quantity and quality
The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial
Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Missing publications? Search for publications with a matching author name.